CD274 and non-small cell lung carcinoma: Additionally, one recent phase 3 trial demonstrated that adjuvant atezolizumab, an immune checkpoint inhibitor, following the platinum‐based chemotherapy could provide disease‐free survival benefit among stage II–IIIA NSCLC patients and specific subgroup of tumors expressing PD‐L1 ≥1%,42 and further immunotherapy, including anti‐PD‐1 and anti‐PD‐L1 agents, is being investigated as adjuvant therapy for patients with resected stage IB to IIIA NSCLC to evaluate the clinical benefit in RFS.43